Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSI-906 plus erlotinib in advanced NSCLC maintenance
NCT01186861Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Mar 2011
- Primary completion
- Jul 2013
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing OSI-906 plus erlotinib with Placebo plus erlotinib (2 arms). Primary endpoint: Progression-Free Survival at 22 months. Started Mar 2011; status: completed.
02
Drugs
linsitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01186861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01186861.